Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN

被引：0

作者：

Munir, Talha ^{[1
]}

Mato, Anthony R. ^{[2
]}

Woyach, Jennifer A. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Ghia, Paolo ^{[6
,7
]}

Patel, Krish ^{[8
]}

Eyre, Toby A. ^{[9
]}

Lech-Maranda, Ewa ^{[10
]}

Lamanna, Nicole ^{[11
]}

Tam, Constantine S. ^{[12
,13
]}

Seymour, John F. ^{[12
,13
]}

Shah, Nirav N. ^{[14
]}

Coombs, Catherine C. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Patel, Manish R. ^{[17
]}

Fakhri, Bita ^{[18
]}

Cheah, Chan Y. ^{[19
,20
]}

Alencar, Alvaro J. ^{[21
]}

Cohen, Jonathon B. ^{[22
]}

Gerson, James N. ^{[23
]}

Flinn, Ian W. ^{[24
]}

Ma, Shuo ^{[25
]}

Jagadeesh, Deepa ^{[26
]}

Rhodes, Joanna M. ^{[27
]}

Hernandez-Ilizaliturri, Francisco ^{[28
]}

Zinzani, Pier Luigi ^{[29
]}

Balbas, Minna ^{[30
]}

Nair, Binoj ^{[30
]}

Abada, Paolo ^{[30
]}

Wang, Chunxiao ^{[31
]}

Wang, Denise ^{[30
]}

Tsai, Donald E. ^{[30
]}

Wierda, William G. ^{[32
]}

Jurczak, Wojciech ^{[33
]}

机构：

[1] St James Hosp, Leeds, W Yorkshire, England

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Harvard Med Sch, Boston, MA USA

[6] Univ Vita Salute San Raffaele, Milan, Italy

[7] IRCCS Osped San Raffaele, Milan, Italy

[8] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[10] Inst Hematol & Transfus Med, Warsaw, Poland

[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[12] Peter MacCallum Canc Ctr, Melbourne, Australia

[13] Univ Melbourne, Melbourne, Australia

[14] Med Coll Wisconsin, Milwaukee, WI USA

[15] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[16] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[17] Florida Canc Specialists Sarah Cannon Res Inst, Sarasota, FL USA

[18] Univ Calif San Francisco, San Francisco, CA USA

[19] Linear Clin Res, Perth, Australia

[20] Sir Charles Gairdner Hosp, Perth, Australia

[21] Univ Miami, Miller Sch Med, Miami, FL USA

[22] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[23] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[24] Sarah Cannon Res Inst, Nashville, TN USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL USA

[26] Cleveland Clin, Cleveland, OH USA

[27] Northwell Hlth, Northwell Hlth Canc Inst, Donald & Barbara Zucker Sch Med Hofstra, New Hyde Pk, NY USA

[28] Roswell Pk Comprehens Canc Ctr, Lymphoma Sect, Dept Med Oncol, Buffalo, NY USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[30] Loxo Lilly, Indianapolis, IN USA

[31] Eli Lilly & Co, Indianapolis, IN USA

[32] MD Anderson Canc Ctr, Houston, TX USA

[33] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO84

引用

页码：110 / 111

页数：2

共 50 条

[21] Pirtobrutinib in Heavily Pre-Treated Richter Transformation: Updated Efficacy and Safety Results with 18-month Median Survival Follow-up from the Phase 1/2 BRUIN Study
Wierda, William G.
Shah, Nirav N.
Cheah, Chan Y.
Lewis, David
Hoffman, Marc S.
Coombs, Catherine C.
Lamanna, Nicole
Shuo, M. A.
Jagadeesh, Deepa
Munir, Talha
Wang, Yucai
Eyre, Toby A.
Rhodes, Joanna
Mckinney, Matthew
Lech-Maranda, Ewa
Tam, Constantine S.
Jurczak, Wojciech
Izutsu, Koji
Alencar, Alvaro
Patel, Manish R.
Seymour, John F.
Woyach, Jennifer
Roeker, Lindsey E.
Thompson, Philip A.
Abada, Paolo
Ho, Caleb
Marella, Narasimha
Wang, Chunxiao
Ruppert, Amy S.
Nair, Binoj
Liu, Hui
Tsai, Donald E.
Ghia, Paolo
Al-Sawaf, Othman
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 120 - 121
[22] LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Eyre, Toby A.
Woyach, Jennifer A.
Wierda, William G.
Cheah, Chan Yoon
Roeker, Lindsey E.
Patel, Manish R.
Fakhri, Bita
Barve, Minal
Tam, Constantine S.
Lewis, David John
Gerson, James N.
Alencar, Alvaro J.
Taylor, Justin
Abdel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
BLOOD, 2020, 136
[23] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
[24] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
[25] Pirtobrutinib in Post-cBTKi CLL/SLL: ∼30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Roeker, Lindsey E.
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Tessoulin, Benoit
Shah, Nirav N.
Ujjani, Chaitra S.
Fakhri, Bita
Coombs, Catherine C.
Flinn, Ian W.
Patel, Manish
Nasta, Sunita D.
Cohen, Jonathon B.
Alencar, Alvaro J.
Cheah, Chan Y.
Ma, Shuo
Rhodes, Joanna M.
Jagadeesh, Deepa
Zinzani, Pier Luigi
Osterborg, Anders
Izutsu, Koji
Tsai, Donald E.
Abada, Paolo
Balbas, Minna
Li, Jian
Ruppert, Amy S.
Jurczak, Wojciech
Wierda, William G.
BLOOD, 2023, 142
[26] Pirtobrutinib in Post-cBTKi CLL/SLL: ∼30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
[27] Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Robert J. Kreitman
Claire Dearden
Pier Luigi Zinzani
Julio Delgado
Tadeusz Robak
Philipp D. le Coutre
Bjørn T. Gjertsen
Xavier Troussard
Gail J. Roboz
Lionel Karlin
Douglas E. Gladstone
Nataliya Kuptsova-Clarkson
Shiyao Liu
Priti Patel
Federico Rotolo
Emmanuel Mitry
Ira Pastan
Francis Giles
Journal of Hematology & Oncology, 14
[28] Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial
Kreitman, Robert J.
Dearden, Claire
Zinzani, Pier Luigi
Delgado, Julio
Robak, Tadeusz
le Coutre, Philipp D.
Gjertsen, Bjorn T.
Troussard, Xavier
Roboz, Gail J.
Karlin, Lionel
Gladstone, Douglas E.
Kuptsova-Clarkson, Nataliya
Liu, Shiyao
Patel, Priti
Rotolo, Federico
Mitry, Emmanuel
Pastan, Ira
Giles, Francis
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[29] Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
Brown, J. R.
Hillmen, P.
O'Brien, S.
Barrientos, J. C.
Reddy, N. M.
Coutre, S. E.
Tam, C. S.
Mulligan, S. P.
Jaeger, U.
Barr, P. M.
Furman, R. R.
Kipps, T. J.
Cymbalista, F.
Thornton, P.
Caligaris-Cappio, F.
Delgado, J.
Montillo, M.
DeVos, S.
Moreno, C.
Pagel, J. M.
Munir, T.
Burger, J. A.
Chung, D.
Lin, J.
Gau, L.
Chang, B.
Cole, G.
Hsu, E.
James, D. F.
Byrd, J. C.
LEUKEMIA, 2018, 32 (01) : 83 - 91
[30] Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J R Brown
P Hillmen
S O’Brien
J C Barrientos
N M Reddy
S E Coutre
C S Tam
S P Mulligan
U Jaeger
P M Barr
R R Furman
T J Kipps
F Cymbalista
P Thornton
F Caligaris-Cappio
J Delgado
M Montillo
S DeVos
C Moreno
J M Pagel
T Munir
J A Burger
D Chung
J Lin
L Gau
B Chang
G Cole
E Hsu
D F James
J C Byrd
Leukemia, 2018, 32 : 83 - 91

← 1 2 3 4 5 →